18F-FDG PET/CT in response evaluation of gastrointestinal stromal tumours treated with imatinib;La PET/TAC con 18F-FDG en la evaluación de la respuesta de los tumores del estroma gastrointestinal al tratamiento con imatinib

Revista Espanola de Medicina Nuclear

Volumn 27, Issue 3, 2008, Pages 168-175

  Banzo, I ^a   Quirce, R ^a   Martinez Rodriguez I ^a   Jimenez Bonilla J F ^a   Sainz Esteban, A ^a   Barragan J ^a   Portilla Quattrociocchi, H ^a   Carril, J M ^a  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

18F fluorodeoxyglucose; Gastrointestinal stromal tumour; Imatinib; PET CT; Response to therapy

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; ANTINEOPLASTIC AGENT; DIAGNOSTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ABDOMINAL LYMPH NODE; ABDOMINAL MASS; ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LYMPH NODE; LYMPH NODE METASTASIS; MALE; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; TREATMENT RESPONSE; TUMOR VOLUME; CLINICAL TRIAL; DRUG MONITORING; GASTROINTESTINAL TUMOR; LIVER TUMOR; LUNG TUMOR; METASTASIS; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; REMISSION; SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG MONITORING; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; RADIOPHARMACEUTICALS; REMISSION INDUCTION; TOMOGRAPHY, X-RAY COMPUTED;

EID: 44949259043     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1157/13121026     Document Type: Article

References (26)

1. Rubin BP, Heinrich MC, Corless Cl. Gastrointestinal stromal tumour. Lancet. 2007;369:1731-41.
2. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med. 2002;347:472-80.
3. Chow LQM, Eckkardt SG. Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 2007;25:884-96.
4. Banzo I, Quirce R, Martínez-Rodríguez I, Jiménez-Bonilla J, Sainz-Esteban A, Barragán J, et al. 18F-FDG PET/CT assessment of the response of gastrointestinal stromal tumor to Sunitinib malate therapy. Clin Nucl Med. 2008;33:211-2.
5. Borrego I, López C, Vázquez R, Ginel A, Barrot E. Evaluación de la eficacia y el impacto clínico de la PET-FDG en los pacientes con carcinoma broncopulmonar no microcítico candidatos a cirugía. Rev Esp Med Nucl. 2007;26:335-44.
6. Jiménez-Bonilla JF, Quirce R, Banzo I, Martínez- Rodríguez I, Sainz-Esteban A, Barragán JE, et al. In-111 Ibritumomab scintigraphy (planar and SPECT) and FDG PET/CT before Y-90 Ibritumomab treatment in a patient with mantle cell lymphoma. Clin Nucl Med. 2007;32:952-3.
7. Rebollo AC, Ramos C, Bellón ME, Cabello D, Gallego M, Rodríguez A, et al. Tomografía por emisión de positrones con 18F-fluordesoxiglucosa en pacientes con sarcoma uterino. Rev Esp Med Nucl. 2007;26:189-95.
8. Quirce R, Banzo I, Jiménez-Bonilla JF, Martínez- Rodríguez I, Sainz-Esteban A, Carril JM. Potenciales fuentes de error diagnóstico y variantes de la FDG-PET/TAC. Rev Esp Med Nucl. 2008;27:130-59.
9. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: Literature-based evidence as of September 2006. J Nucl Med. 2007;48 Suppl:S78-88.
10. Weber WA, Figlin R. Monitoring cancer treatment with PET/CT: Does it make a difference? J Nucl Med. 2007;48 Suppl:S36-44.
11. Alberini JL, Al Nakib M, Wartski M, Gontier E, Cvitkovic F, Rixe O, et al. The role of PET scan in gastrointestinal stromal tumors. Gastroenterol Clin Biol. 2007;31:585-93.
12. Simó M, García JR, Soler M, Pérez G, López S, Lomeña FJ. Utilidad de la PET con FDG en el estudio de estadificación inicial, recurrencia y respuesta al tratamiento con Imatinib (Glivec) en pacientes diagnosticados de un tumor del estroma gastrointestinal. Rev Esp Med Nucl. 2006;25:80-8.
13. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of Imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med. 2004;45:357-65.
14. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: Long-term outcome of treatment with Imatinib mesylate. Eur J Nucl Med Mol Imaging. 2005;32:153-62.
15. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, et al. The role of 18F-FDG in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med. 2004;45:17-21.
16. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38 Suppl 5:S60-5.
17. Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma AA, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-82.
18. Jaffe CC. Measures of response: RECIST, WHO, and new alternatives. J Clin Oncol. 2006;24:3245-51.
19. Hong X, Choi H, Loyer EM, Benjamin RS, Trent JC, Charnsangavej CH. Gastrointestinal stromal tumor: Role of CT in diagnosis and in response evaluation and surveillance after treatment with Imatinib. Radiographics. 2006;26:481-95.
20. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760-4.
21. Choi H, Charnsangavej CH, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753-9.
22. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, et al. CT and PET: Early prognostic indicators of response to Imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol. 2007;189:W324-30.
23. Jager PL, Gietema JA, van der Graaf WTA. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun. 2004;25:433-8.
24. Delgado RC, Ortega A, Pérez-Castejón MJ, Garcerant M, Cabrera MN, Lapeña L, et al. PET 18F-FDG en la detección temprana de la respuesta al tratamiento con Glivec en paciente con tumor del estroma gastrointestinal. Rev Esp Med Nucl. 2008;27:112-7.
25. García-González J, Sánchez A, Areses C, León L, Barandela J, López R. Utilidad de la FDG-PET en la evaluación precoz de la eficacia de Imatinib (Glivec) en el tratamiento de tumores del estroma gastrointestinal. Rev Esp Med Nucl. 2007;26:100-2.
26. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Eng J Med. 2006;354:496-507.